FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4311141809> ?p ?o ?g. }

• W4311141809 endingPage "100132" @default.
• W4311141809 startingPage "100132" @default.
• W4311141809 abstract "Melanoma, from its early stages, has a natural propensity to spread, that is regulated via constant immune counteraction. Unleashing adaptive immunity via ICIs has improved melanoma prognosis, but not all patients behave similarly under immunotherapy. Some relapse in the first few months of immunotherapy, while others experience durable disease control, even after discontinuation of ICIs. In order to identify any cellular/molecular signature in the peripheral blood that could predict primary immune escape, we examined 100 consecutive patients with stage III or IV melanoma who were scheduled to start ICIs. A multiparameter flow cytometry was used to detect differences in immune subpopulations, gating them by standard conjugated antibodies and mRNA was extracted after sorting of CD3+CD4+T-cells. A gene ontology (GO) enrichment analysis was performed to recognize which specific genes and key pathways are upregulated in stage III and IV melanoma and between long responders (>36 months) and early progressors(<6 months) to ICIs. Although circulating immune cells did not differ numerically in patients with stage III and IV melanoma as well as in responders and non-responders to ICIs, transcriptomic analysis of CD3+CD4+T-cells from 24 selected patients showed that 189 genes were upregulated in stage IV vs. 92 in stage III; while 101 genes were upregulated in early progressors vs. 47 in long responders. These differentially expressed genes (e.g., HLA-DRB5, BCL3, TRIM37, NCAM1, FGFR1) were functionally implicated in distinct cellular pathways that were particularly activated in these two settings. In fact, biological GO pathways of adaptive immunity, negative regulation of DNA-binding transcription factor activity, and lipid metabolism were significantly more upregulated in stage IV compared to stage III melanoma; while phosphorylation of CD3 and TCR chains, PD-1 and IFN signaling were more activated in early progressors compared to long responders to ICIs. Extrapolating the rules of intra-tumoral plasticity to the blood, specific epigenetically altered pathways in the peripheral CD3+CD4+T-cells may differentiate the melanoma evolution from stage III to IV and drive the resistance to ICIs." @default.
• W4311141809 created "2022-12-23" @default.
• W4311141809 creator A5025498086 @default.
• W4311141809 creator A5030452785 @default.
• W4311141809 creator A5037385946 @default.
• W4311141809 creator A5040113702 @default.
• W4311141809 creator A5050395315 @default.
• W4311141809 creator A5064814771 @default.
• W4311141809 creator A5080802392 @default.
• W4311141809 date "2022-12-01" @default.
• W4311141809 modified "2023-09-30" @default.
• W4311141809 title "27P Gene ontology enrichment analysis of peripheral CD3+CD4+T cells predicts the immune-mediated behavior of melanoma" @default.
• W4311141809 doi "https://doi.org/10.1016/j.iotech.2022.100132" @default.
• W4311141809 hasPublicationYear "2022" @default.
• W4311141809 type Work @default.
• W4311141809 citedByCount "0" @default.
• W4311141809 crossrefType "journal-article" @default.
• W4311141809 hasAuthorship W4311141809A5025498086 @default.
• W4311141809 hasAuthorship W4311141809A5030452785 @default.
• W4311141809 hasAuthorship W4311141809A5037385946 @default.
• W4311141809 hasAuthorship W4311141809A5040113702 @default.
• W4311141809 hasAuthorship W4311141809A5050395315 @default.
• W4311141809 hasAuthorship W4311141809A5064814771 @default.
• W4311141809 hasAuthorship W4311141809A5080802392 @default.
• W4311141809 hasBestOaLocation W43111418091 @default.
• W4311141809 hasConcept C104317684 @default.
• W4311141809 hasConcept C114684123 @default.
• W4311141809 hasConcept C127561419 @default.
• W4311141809 hasConcept C167672396 @default.
• W4311141809 hasConcept C203014093 @default.
• W4311141809 hasConcept C2777658100 @default.
• W4311141809 hasConcept C2777701055 @default.
• W4311141809 hasConcept C502942594 @default.
• W4311141809 hasConcept C54355233 @default.
• W4311141809 hasConcept C71924100 @default.
• W4311141809 hasConcept C86803240 @default.
• W4311141809 hasConcept C8891405 @default.
• W4311141809 hasConceptScore W4311141809C104317684 @default.
• W4311141809 hasConceptScore W4311141809C114684123 @default.
• W4311141809 hasConceptScore W4311141809C127561419 @default.
• W4311141809 hasConceptScore W4311141809C167672396 @default.
• W4311141809 hasConceptScore W4311141809C203014093 @default.
• W4311141809 hasConceptScore W4311141809C2777658100 @default.
• W4311141809 hasConceptScore W4311141809C2777701055 @default.
• W4311141809 hasConceptScore W4311141809C502942594 @default.
• W4311141809 hasConceptScore W4311141809C54355233 @default.
• W4311141809 hasConceptScore W4311141809C71924100 @default.
• W4311141809 hasConceptScore W4311141809C86803240 @default.
• W4311141809 hasConceptScore W4311141809C8891405 @default.
• W4311141809 hasLocation W43111418091 @default.
• W4311141809 hasOpenAccess W4311141809 @default.
• W4311141809 hasPrimaryLocation W43111418091 @default.
• W4311141809 hasRelatedWork W1996150995 @default.
• W4311141809 hasRelatedWork W2268266875 @default.
• W4311141809 hasRelatedWork W2353561723 @default.
• W4311141809 hasRelatedWork W2359944022 @default.
• W4311141809 hasRelatedWork W2367826053 @default.
• W4311141809 hasRelatedWork W2375963452 @default.
• W4311141809 hasRelatedWork W2388565483 @default.
• W4311141809 hasRelatedWork W2539555867 @default.
• W4311141809 hasRelatedWork W3167775801 @default.
• W4311141809 hasRelatedWork W6572435 @default.
• W4311141809 hasVolume "16" @default.
• W4311141809 isParatext "false" @default.
• W4311141809 isRetracted "false" @default.
• W4311141809 workType "article" @default.